These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31929430)

  • 1. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
    Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
    Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease.
    Orsatti L; Stiehl T; Dischinger K; Speziale R; Di Pasquale P; Monteagudo E; Müller-Tidow C; Radujkovic A; Dreger P; Luft T
    Cell Rep Med; 2021 Oct; 2(10):100409. PubMed ID: 34755129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker Panel for Chronic Graft-Versus-Host Disease.
    Yu J; Storer BE; Kushekhar K; Abu Zaid M; Zhang Q; Gafken PR; Ogata Y; Martin PJ; Flowers ME; Hansen JA; Arora M; Cutler C; Jagasia M; Pidala J; Hamilton BK; Chen GL; Pusic I; Lee SJ; Paczesny S
    J Clin Oncol; 2016 Aug; 34(22):2583-90. PubMed ID: 27217465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.
    Luft T; Benner A; Jodele S; Dandoy CE; Storb R; Gooley T; Sandmaier BM; Becker N; Radujkovic A; Dreger P; Penack O
    Lancet Haematol; 2017 Sep; 4(9):e414-e423. PubMed ID: 28733186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
    El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
    Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.
    Dai H; Rachakonda SP; Penack O; Blau IW; Blau O; Radujkovic A; Müller-Tidow C; Dreger P; Kumar R; Luft T
    Blood Cancer J; 2021 Feb; 11(2):42. PubMed ID: 33640906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
    Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.
    Kitko CL; Levine JE; Storer BE; Chai X; Fox DA; Braun TM; Couriel DR; Martin PJ; Flowers ME; Hansen JA; Chang L; Conlon M; Fiema BJ; Morgan R; Pongtornpipat P; Lamiman K; Ferrara JL; Lee SJ; Paczesny S
    Blood; 2014 Jan; 123(5):786-93. PubMed ID: 24363401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
    Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
    Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
    Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of diagnosis, management, and grading of chronic GVHD.
    Lee SJ; Vogelsang G; Gilman A; Weisdorf DJ; Pavletic S; Antin JH; Horowitz MM; Akpek G; Flowers ME; Couriel D; Martin PJ
    Biol Blood Marrow Transplant; 2002; 8(1):32-9. PubMed ID: 11846354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data.
    Crocchiolo R; Saillard C; Signori A; Fürst S; El Cheikh J; Castagna L; Oudin C; Granata A; Faucher C; Devillier R; Crocchiolo D; Sormani MP; Chabannon C; Blaise D
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):576-83. PubMed ID: 23270984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients.
    Nakasone H; Binh PN; Yamazaki R; Tanaka Y; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kimura S; Kikuchi M; Kako S; Okuda S; Oshima K; Tanihara A; Nishida J; Abe Y; Kanda Y
    Blood; 2011 Mar; 117(12):3469-72. PubMed ID: 21258011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
    Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
    Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival.
    Kordelas L; Buttkereit U; Heinemann FM; Horn PA; Giebel B; Beelen DW; Reinhardt HC; Rebmann V
    Front Immunol; 2021; 12():694843. PubMed ID: 34630383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease].
    Chen T; Li XP; Zhang C; Kong PY; Gao QG; Tang L; Wang R; Yang SJ; Gao L; Liu Y; Gao L; Feng YM; Rao J; Peng XG; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):948-952. PubMed ID: 31856446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.